N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
N/A N=284 Stroke Swallowing Screening Tool Validation
Cerebrovascular Disorders · Deglutition Disorders
Primary: Sensitivity of Screening Items — 37.9; 3.5; 62.1; 10.3 percentage of agreement
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 2 N=81 Bolus of Saline in Stroke
Ischemic Stroke
Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…
N/A N=258 Stroke Self-Management: Effect on Function and Stroke Specific Quality of Life
Stroke
Primary: Total Stroke Specific Quality of Life — 3.80; 3.82; 4.01; 3.94 units on a scale — p=0.0500
N/A N=222 Stroke Team Remote Evaluation Using a Digital Observation Camera
Stroke
Primary: Appropriateness of Decision to Treat or Not Treat With Thrombolytics — 98; 82 percentage of participants
Phase 2 N=163 Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Chronic Ischemic Stroke
Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=120 Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke
Nonhemorrhagic Ischemic Stroke · Motor Function
Primary: Mean Change From Baseline in Total Simplified-STroke Rehabilitation Assessment of Movement (S-STREAM) Score in Participants Obtained Between 24 and 48 Hours of a…
N/A N=984 Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry
Ischemic Stroke
Primary: Number of Participants Assessed for Revascularization With mTICI Grades 2b-3 — 724 Participants
Phase 2 N=13 Stroke Feasibility Study
Atrial Fibrillation · AFib
Primary: Number of Serious Adverse Events Within 30 Days Post-Index Procedure — 0 participants
N/A N=36 Stroke and CPAP Outcome Study 3
Ischemic Stroke · Intra Cerebral Hemorrhage · Obstructive Sleep Apnea
Primary: CPAP Adherence — 3.1 nightly hours of CPAP use
N/A N=83 Stroke Telemedicine Outpatient Prevention Program for Blood Pressure Reduction
Stroke Prevention · Blood Pressure · Telemedicine
Primary: Daytime Ambulatory Systolic Blood Pressure — 123.6; 128.3 millimeters of mercury (mmHg)
Phase 4 N=80 Human Urinary Kallidinogenase Improve Short Term Motor Functional Outcome of Acute Ischemia Stroke Patients
Stroke, Acute
Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml
Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=400 Investigation of Clot in Ischemic Stroke and Hematoma Evacuation
Ischemic Stroke · Intracranial Hematoma
Primary: Clot Specimen Histology — 373; 12 Count of specimen
Phase 2 N=14 Cough and Swallow Rehab Following Stroke
Ischemic Stroke
Primary: Maximum Expiratory Pressure — 104.31 cm H2O (pressure measurement) — p=.001
Phase 2 N=33 Mayo Acute Stroke Trial for Enhancing Recovery
Ischemic Stroke
Primary: Percent of Participants With National Institutes of Health Stroke Scale (NIHSS) Score = 0 or 1 at Day 90 — 69; 33; 0; 45 percentage of participants
Phase 4 N=2,716 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
Cerebral Infarction
Primary: Numbers of Patients With First Occurence of Stroke — 82; 119 participants — p=0.0357
Phase 2 N=241 Normal Saline Infusion for Stroke After Intravenous Thrombolysis
Brain Infarct
Primary: Number of Participants With 90-day Favorable Outcome — 106; 93 Participants
Phase 1 N=23 Safety Study of External Counterpulsation as a Treatment for Acute Ischemic Stroke
Stroke
Primary: Feasibility and Tolerability of External Counterpulsation — 12; 9 participants
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=600 Prevent Return of Stroke Study
Stroke Recurrence · Transient Ischemic Attack
Primary: Blood Pressure — 76; 65 percentage of participants
Phase 2 N=18 A Study of Modified Stem Cells in Stable Ischemic Stroke
Chronic Ischemic Stroke
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants
Phase 3 N=1,489 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity
Stroke
Primary: Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1 — 72.7; 70.3 Percentage of participants